

AUTHOR INDEX

- Anghelescu, D.L., 53
 Bauer-Wu, S., 115, 122
 Champion, V.L., 252
 Deatrick, J.A., 101, 105
 Drew, D., 142
 Drotar, D., 98, 105
 Edwards, D.M., 153, 154
 Esper, P., 20
 Evans, R.C., 184
 Giarelli, E., 271
 Gierisch, J.M., 286
 Gordon, J.S., 154
 Greenwald, P., 296
 Hare, M.L., 145
 Harvey, J., 122
 Hawks, R.G., 107, 122
 Heidrich, D., 20
 Hibdon, S.S., 196
 Hicks, J., 53
 Himmelstein, B.P., 134, 142
 Hinds, P.S., 53, 77, 79, 125, 142
 Jacobs, L.A., 271
 Kelly, K.M., 119, 122
 Kelly, K.P., 79, 89, 105
 Kemp, C., 44
 Kinlaw, K., 63
 Kuebler, K.K., 1, 2, 36
 LaFond, D.A., 125, 142
 Laizner, A.M., 122
 Lee, C.C.O., 201
 Lu, W., 190
 Lynn, J., 2
 MacDonald, N., 69
 Mahon, S.M., 260
 Maritess, C., 173
 Meyskens, F.L., Jr, 229
 Meza, J., 105
 Mihelic, R.A., 29
 Moore, C.D., 11
 Nuss, S.L., 125, 142
 Oakes, L.L., 53
 Padberg, R.M., 227, 243
 Phillips, J.M., 278
 Post-White, J., 107, 122, 215
 Pyke-Grimm, K.A., 89, 105
 Rawl, S.M., 252
 Rimer, B.K., 286
 Rosner, A.L., 184
 Ruccione, K.S., 79
 Rushton, C.H., 138, 142
 Rutledge, D.N., 36
 Sanford, K., 164
 Singh, G.K., 236
 Small, S., 173
 Smith, J.J., 227, 243
 Stegenga, K.A., 105
 Stewart, J.L., 89, 105
 Stutzer, C.A., 142
 Taylor, E.J., 159
 Treasure, J., 177
 Tully, P., 229, 243
 Von Rohen, J., 2
 Wallace, J.D., 77, 79
 Waltz-Hill, M., 173
 Williams-Brown, S., 236, 278
 Wyatt, G., 215
 Zavala, O., 105

SUBJECT INDEX

- Acute leukemia, second primary, associated with lymphoma, 269
 Adenoma Prevention with Celecoxib, chemoprevention trial for colon cancer, 251
 Breast cancer
 association with second primary cancers
 breast cancer, 266
 colorectal cancer, 267
 endometrial cancer, 266
 other cancers, 267
 ovarian cancer, 266-267
 chemoprevention clinical trials
 Breast Cancer Prevention Trial (BCPT), 248
 Study of Tamoxifen and Raloxifen, 248
 risk in the US, epidemiologic study designs of, 240
 second primary, associated with
 colorectal cancer, 268
 endometrial cancer, 268
 lymphoma, 270
 ovarian cancer, 267
 Breast Cancer Prevention Trial (BCPT), 248
 Cancer
 chemoprevention clinical trials
 breast cancer, 248
 chemopreventive agents in, 247
 colon cancer, 250-251
 endpoints in, 247
 head and neck cancer, 250
 lung cancer, 249-250
 nursing implications, 251
 prostate cancer, 249
 skin cancer, 250
 study populations in, 246-247
 epidemiology in the US
 economic burden and, 241
 etiology and underlying risk factors, 239
 historical perspective, 238
 incidence and mortality, 238
 prevention and control policies and programs, 241-242
 secondary prevention and use of screening tests, 240-241
 study designs of breast cancer risk, 240
 surveillance and, 241
 trends in incidence, 238-239
 trends in mortality, 239
 prevention, 227-228
 carcinogenesis and, 230-231
 clinical trials in, 233-234
 epidemiology and, 232-233
 future of, 299-302
 risk factors in, 273-278
 role of genetics and genes, 231-232
 second primary, 262-271
 types, 234
 primary prevention. *See* Primary cancer prevention
 public education and, 288-296
 among racial ethnic minorities
 incidence, mortality and survival, 281-282
 national initiatives and community-based programs, 284-286
 primary prevention, 283
 secondary prevention, 284
 risk factors
 colorectal cancer, 277
 concepts applied to modification of, 277-278
 conceptualizing modifiability, 276-277
 conceptualizing risk, 274-275
 gene-environment interaction and, 275-276
 genetic and environmental, 274
 implications for nurses, 278